

BALANCE SHEETS

	March 31, 2026	March 31, 2025
	U.S. Dollars	U.S. Dollars
	Unaudited	Unaudited
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	1	1
Short-term bank deposits	-	-
Current maturities of LT Bank Deposits	-	-
Restricted short term bank deposit	-	-
Marketable Securities	-	-
Trade accounts receivable	-	-
Other receivables and prepaid expenses:		
Prepaid expenses	-	-
Deferred income taxes	-	-
Government authorities	-	-
Advances to suppliers	-	-
Derivative instruments	-	-
Intercompany balances	-	-
Other	-	-
TOTAL Other receivables and prepaid expenses	-	-
Inventories	-	-
TOTAL CURRENT ASSETS	1	1
Long Term Receivables and Other Assets	-	-
Long Term Marketable Securities	-	-
ROU Assets, net	-	-
FIXED ASSETS:		
Cost	-	-
Less - accumulated depreciation	-	-
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	-	-
DEFERRED INCOME TAXES	-	-
TOTAL ASSETS	\$ 1	\$ 1

BALANCE SHEETS

	March 31, 2026	March 31, 2025
	U.S. Dollars	U.S. Dollars
	Unaudited	Unaudited
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Short-term bank credit	\$ -	\$ -
Current maturities of long-term debt	-	-
Accounts payable:		
Trade payables	-	-
Other current liabilities:		
Returns reserve	-	-
Due to customers	-	-
Intercompany balances	-	-
Lease Liability	-	-
Employees and payroll accruals	-	-
Current Maturities of Long Term Incentive Plan (LTIP)	-	-
Deferred revenue	-	-
Accrued income taxes	-	-
Legal and audit fees	-	-
Settlements and loss contingencies	-	-
Accrued expenses	-	-
Interest payable	-	-
Derivative instruments	-	-
Deferred taxes	-	-
Suppliers of property, plant and equipment	-	-
Payable on Purchase of treasury stock	-	-
Payable on Purchase of Marketable Securities	-	-
Other	-	-
TOTAL Other current liabilities	-	-
TOTAL CURRENT LIABILITIES	-	-
LONG-TERM LIABILITIES:		
Long-term debt, net of current maturities	-	-
Deferred income taxes	-	-
Derivative instruments	-	-
Other long-term liabilities	-	-
SHAREHOLDERS' EQUITY	1	1
	\$ 1	\$ 1

Date of approval of the
financial statements

Zvi Albert
Vice President, Finance and CFO

STATEMENTS OF INCOME

	For the Year Ended	For the Year Ended
	March 31, 2026	March 31, 2025
	U.S. Dollars	U.S. Dollars
	Unaudited	Unaudited
Sales	\$ -	\$ -
Cost of sales	-	-
Gross profit	-	-
Research and development	-	-
Selling and marketing expenses	-	-
Settlements and loss contingencies	-	-
General and administrative expenses	-	-
Operating income	-	-
Financing income, net	-	-
Other income	-	-
Income before taxes on income	-	-
Taxes on income	-	-
Discontinued operation	-	-
Net income for the period before subsidiaries and dividend	-	-
Dividend income, net	-	-
Subsidiaries	-	-
Net income for the period	\$ -	\$ -

Taro Pharma Corporation, Inc.

Changes in Shareholders' Equity

	Share Capital	Additional paid in capital	Accumulated other comprehensive loss	Treasury stock	Dividend	Retained Earnings	Total Shareholders' Equity
	U.S. Dollars						
	Un-audited						
Issuance of shares	1						1
Net income							-
Balance at March 31, 2025	1	-	-	-	-	-	1
Net income							-
Balance at March 31, 2026	1	-	-	-	-	-	1